CD80 Antikörper
Kurzübersicht für CD80 Antikörper (ABIN2689409)
Target
Alle CD80 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Marke
- BD Pharmingen™
-
Produktmerkmale
-
The 1G10 antibody reacts with CD80 (B7-1). This member of the Ig superfamily, along with CD86 (B7-2), participates in T-cell costimulation via interactions with CD28 and CD152 (CTLA-4). CD80 is constitutively expressed on dendritic cells, monocytes, and peritoneal macrophages, and it is inducible on B cells by various means, including activation by LPS, IL-4, and the cross-linking of surface Ig. Expression of CD80 is greatly enhanced on splenic B cells following activation by LPS, with peak expression occurring between 48 and 72 hours. It has been reported that activation of purified B cells with LPS can induce CD80 expression in as few as 18 hours. The 1G10 antibody blocks binding of CTLA-4-Ig to CD80, but it does not block stimulation of T cells by natural antigen-presenting cells. Preliminary evidence has shown that mAb 16-10A1 (Cat. no. 553766) blocks binding of 1G10 mAb to CD80, indicating that the two antibodies may recognize overlapping epitopes on the CD80 Molecule. However, the 16-10A1 mAb recognizes an upregulated antigen on UV-irradiated P815 mastocytoma cells which is not detected by the 1G10 mAb, the cause and significance of this differential reactivity of the two anti-CD80 antibodies is unknown. Expression of membrane CD80 (B7-1) by mouse splenocytes. Freshly isolated (left) or 72-hour LPS-stimulated BALB/c splenocytes (right) were stained with purified 1G10/B7 mAb (open histograms) or no primary mAb (shaded histograms). Staining was detected with biotinylated goat anti-rat Ig (Cat. No. 554014) followed by Streptavidin-PE (Cat. No. 554061). Viable resting lymphocytes (left) and blasts (right) were selected by scatter profile and dye exclusion (BD Pharmingen™ Via-Probe™, Cat. No. 555816/555815). Flow cytometry was performed on a FACScan™ .
BD Pharmingen™ Purified Rat Anti-Mouse CD80 - Purified - Clone 1G10/B7 - Isotype Rat IgG2a, κ - Reactivity Ms - 0.5 mg -
Aufreinigung
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
-
Immunogen
- Activated Mouse 5C2 Cells
-
Isotyp
- IgG2a kappa
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.5 mg/mL
-
Buffer
- Aqueous buffered solution containing ≤0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store undiluted at 4°C.
-
-
-
: "Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 164, Issue 12, pp. 6230-6, (2000) (PubMed).
: "New perspectives of CD28-B7-mediated T cell costimulation." in: Immunity, Vol. 2, Issue 6, pp. 555-9, (1995) (PubMed).
: "Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance." in: Current opinion in immunology, Vol. 6, Issue 5, pp. 797-807, (1995) (PubMed).
: "Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function." in: The Journal of experimental medicine, Vol. 180, Issue 2, pp. 631-40, (1994) (PubMed).
: "Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression." in: Nature, Vol. 360, Issue 6401, pp. 266-8, (1992) (PubMed).
-
: "Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 164, Issue 12, pp. 6230-6, (2000) (PubMed).
-
- CD80
-
Andere Bezeichnung
- CD80
-
Hintergrund
- Synonyms: B7-1
-
Pathways
- T-Zell Rezeptor Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-